Librairie scientifique

• Inhibiteur de protéase du VIH PPL-100
• Inhibiteurs d'intégrase du VIH
• Technologie de libération NGR
• Trousse de tests PSP94

Inhibiteur de protéase du VIH PPL-100

Articles

• Dandache, S. et al. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007 Nov;51(11):4036-43. Epub 2007 Jul 16.
• Stranix, B., et al. Lysine sulfonamides as Novel HIV-Protease Inhibitors: Optimization of the Nε-Acyl-Phenyl Spacer. Bioorganic and Medicinal Chemistry Letters 2003, Vol. 13, pp 4289 - 4292.

Présentations

• Wu, J.J. et al. PL-100, a Next Generation Protease Inhibitor against Drug-Resistant HIV: In Vitro and In Vivo Metabolism. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) tenu à San Francisco, Septembre 2006.
• Dandache, S. et al. PL-100, a Novel Protease Inhibitor with a High Genetic Barrier. XVI International AIDS Conference, Toronto, Canada, Août 2006.
• Wu, J.J. et al. The HIV-1 Protease Inhibitor PL-100 Has a High Genetic Barrier and Selects a Novel Patterns of Mutations. XV International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Sitges, Espagne, Juin 2006.
• Wu, J. et al. PPL-100 and its derivatives, a novel class of potent human immunodeficiency virus type 1 protease inhibitors: resistance and pharmacokinetics. XIV International HIV Drug Resistance Workshop, Québec, Canada, Juin 2005.
• Wu, J. et al. Pharmacological and cross-resistance profiling of PL-100 and its pro-drug, PPL-100. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Québec, Canada, Avril 2005.
• Sévigny, G, et al. Cross-resistance profile of the novel lysine-containing HIV-1 protease inhibitor PL-100. XIII International HIV Drug Resistance Workshop, Iles Canaries, Espagne, Juin 2004.
• Sévigny, G, et al. Improving the resistance profile of HIV-1 protease inhibitors. Protease Targets and Drug Discovery Symposium, Philadelphie, PA, É.-U., Décembre 2003.
• Stranix, B., et al. Synthesis and SAR studies of novel HIV protease inhibitors, containing a lysine backbone. 39th International Union of Pure and Applied Chemistry Congress and 86th Conference of the Canadian Society For Chemistry, Ottawa, Canada, Août 2003.
• Sévigny, G. et al. Antiviral activity of P-1946, a novel anti-HIV protease inhibitor. XII International HIV Drug Resistance Workshop, Los Cabos, Mexique, Juin 2003.

Inhibiteurs d'intégrase du VIH

Présentations

• Small Molecule Inhibitors of HIV-1 Integrase 17e colloque international sur la résistance du VIH aux médicaments, Sitges, Espagne, 10-14 juin 2008.
• Pyrazolopyridine compounds as novel HIV-1 integrase inhibitors Poster 47e Conférence ICAAC , Chicago, 17-20 septembre, 2007.
• Novel smal molecule inhibitors of HIV-1 integrase Poster Colloque sur la résistance du VIH aux médicaments, Barbades, 12-16 juin, 2007.

Technologie de libération NGR

Articles

• Pastorino, F. et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003;63(21):7400-7409
• Curnis, F., et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 2002 62(3):867-874

Présentations

• Garde, S., et al. TVT-Dox: in vivo efficacy and in vitro molecular mechanism of action. AACR 2007, Los Angeles, California, USA, April 14-18, 2007.
• Wu, J.J., et al. A novel dual-targeting drug for the solid tumors and their vasculature. 2006 Miami Nature Biotechnology Winter Symposium Angiogenesis in Cancer and Vascular Disease, Miami Beach, Floride, Février 2006.
• Meyer, O.,et al. Assay methods for binding NGR-targeted liposomal doxorubicin using cells expressing the angiogenic marker CD13. Lipids, Liposomes & Biomembranes, new technologies, UBC, Vancouver, Canada, Juillet 2005.
• Meyer, O., et al. Preclinical efficacy of tumor vasculature targeted liposomal doxorubicin. Royal Society of Canada (RSC)/ Korean Academy of Science and Technology (KAST) 3rd Bilateral Symposium: Drug Delivery Systems, Vancouver, Canada, July 2005.

Trousse de tests PSP94

Articles

• Reeves, J., et al. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Imaging, Diagnosis, Prognosis, Clinical Cancer Research Res 2006;12(20) October 15, 2006
• Nam, R., et al. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. The Journal of Urology Vol. 175, 1291-1297, April 2006
• Reeves, J., et al. Identification, purification and characterization of a noval human blood protein with bnding affinity for prostate secretory protein of 94 amino acids. Biochem. J.(2005) 385, 105-114